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Abstract
Aims/hypothesis The prevalence of gestational diabetes mellitus (GDM) is increasing worldwide in all ethnic groups. Low
vitamin B12 and low/high folate levels may contribute to GDM risk, but there is conflicting evidence. Our aim is to assess the
relationships of early pregnancy vitamin B12 and folate levels with the risk of GDM status at 26–28 weeks of gestation.
Methods This was a prospective, multi-centre, multi-ethnic cohort study (n = 4746) in the UK. Participants who were eligible to
be selectively screened as per the National Institute for Health and Care Excellence (NICE) criteria were included in the study.
Results GDM prevalence was 12.5% by NICE and 14.7% by International Association of Diabetes and Pregnancy Study Groups
(IADPSG) criteria. Folate deficiency (1.3%) was rare but B12 insufficiency (42.3% at <220 pmol/l) and folate excess (36.5%)
were common in early pregnancy. Early pregnancy median B12 levels were lower, and folate levels higher, in women who were
diagnosed with GDM at 26–28 weeks. B12 was negatively associated with fasting plasma glucose (1 SD: −0.06 mmol/l; 95% CI
−0.04, −0.08; p < 0.0001) and 2 h plasma glucose levels (−0.07 mmol/l; 95% CI −0.02, −0.12; p = 0.004). Higher B12 was
associated with 14.4% lower RR of IADPSG-GDM (0.856; 95%CI 0.786, 0.933; p = 0.0004) after adjusting for key confounders
(age, parity, smoking status, ethnicity, family history, household income and folate status). Approximately half of this association
was mediated through BMI. Folate was positively associated with 2 h plasma glucose levels (0.08 mmol/l; 95% CI 0.04, 0.13;
p = 0.0005) but its relationship with fasting plasma glucose was U-shaped (quadratic β: 0.011; p = 0.05). Higher folate was
associated with 11% higher RR of IADPSG-GDM (adjusted RR 1.11; 95% CI 1.036, 1.182; p = 0.002) (age, parity, smoking
status, ethnicity, family history, household income and B12 status). Although no interactions were observed for B12 and folate (as
continuous variables) with glucose levels and GDM risk, a low B12–high folate combination was associated with higher blood
glucose level and risk of IADPSG-GDM (adjusted RR 1.742; 95% CI 1.226, 2.437; p = 0.003).
Conclusions/interpretation B12 insufficiency and folate excess were common in early pregnancy. Low B12 and high folate levels
in early pregnancy were associated with small but statistically significant changes in maternal blood glucose level and higher RR
of GDM. Our findings warrant additional studies on the role of unmetabolised folic acid in glucose metabolism and investigating
the effect of optimising early pregnancy or pre-conception B12 and folate levels on subsequent hyperglycaemia.
Trial registration: ClinicalTrials.gov NCT03008824.
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Gestational diabetes mellitus (GDM) is a common medical
disorder in pregnancy, estimated to affect more than 20
million pregnancies worldwide, and causes significant short-
and long-term consequences to both the women and their
offspring [1]. While management of GDM reduces the
short-term complications, it does not abolish them completely
[2, 3]. In addition, adverse effects for the offspring may have
already happened prior to the diagnosis of GDM [4–6].
Therefore, prevention of GDM would be a better approach
to reduce adverse outcomes in pregnant women and their
offspring. This will require identifying and modifying risk
factors before the diagnosis of GDM. However, most preven-
tion studies in early pregnancy (such as diet and lifestyle inter-
ventions) have focused on a single modifiable risk factor,
obesity, with limited success. Identification of other modifi-
able risk factors that contribute to GDM risk is needed.
Folate and B12 are essential micronutrients for the metab-
olism of single carbon atoms (known as 1-C metabolism) and
these pathways are involved in DNA methylation and synthe-
sis of amino acids, nucleic acids and lipids [7, 8]. High total
homocysteine (tHcy) is a marker of deficiency of either nutri-
ent as B12 is a coenzyme for the folate-dependent methylation
of tHcy to methionine. In addition, B12 is a coenzyme for the
action of methyl malonyl-CoA mutase in the mitochondria,
involved in the conversion of methyl malonyl-CoA to succi-
nyl-CoA, and degradation of odd-chain fatty acids and
branched-chain amino acids (BCAAs) [7, 8]. Altered levels
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of BCAAs have been shown to precede the onset of
hyperglycaemia and type 2 diabetes [9]. Folate and B12 thus
play a crucial and inter-dependent role in genomic stability,
methylation potential, epigenetics, carbohydrate metabolism,
fatty acid β-oxidation and protein synthesis [7, 8]. Some of
these mechanisms contribute to glucose homeostasis as well
as adverse metabolic programming of the offspring [10–12].
Conflicting data have been reported regarding associations
of B12 and folate with the risk of GDM. Most of the studies
measured these B vitamins at the time of diagnosis of GDM in
late pregnancy or used estimated folate intake [13–21]. Higher
tHcy has been linked to impaired endothelial function, with
resulting reduction in insulin sensitivity, outside pregnancy
[22], but its role in glucose metabolism in pregnancy is not
clear. Previous studies showed positive, negative or no asso-
ciations with the risk of GDM [23–26]. The purpose of our
study is to examine the relationships of B12, folate and tHcy
levels in early pregnancy with the glucose levels and risk of
GDM in late pregnancy, in a large, multi-ethnic, prospective
cohort study.
Methods
Participant selection and recruitment
Pregnant women attending antenatal care in ten study sites
across the UK were recruited between 2012 and 2018 to the
‘Micronutrients in Pregnancy as a Risk Factor for Gestational
Diabetes and Effects on Mother and Baby’ (PRiDE) study
(clinicaltrials.gov number: NCT03008824). Ethical approval
was obtained from the National Research Ethics Committee
(12/WM/0010). All participants provided written informed
consent. The detailed study protocol, including all the
standard operating procedures, is available at the departmental
website, University of Warwick (https://warwick.ac.uk/fac/sci/
med/staff/saravanan/pride_study_protocol.pdf). In brief,
pregnant women aged between 18 and 45 years who were at
less than 16 weeks of gestation and fulfilled the National
Institute for Health and Care Excellence (NICE) criteria for
screening for GDM were included [27]. All centres followed
theNICE screening guidelines (at least one of the following risk
factors): BMI ≥30 kg/m2; previous GDM; previous unex-
plained stillbirth or birthweight ≥4.5 kg; first degree relative
with diabetes; ethnic minority group. Two centres screened
additional women who were aged ≥35 years at booking or
had a history of polycystic ovarian syndrome. The exclusion
criteria were: pre-gestational diabetes mellitus; a previous preg-
nancywith a neural tube defect; multiple gestation; severe anae-
mia (haemoglobin <10 g/dl); confirmed vitamin B12 or folate
deficiency or having received B12 injections within the last
6 months.
Data collection
Participants’ demographic information including their marital,
employment and smoking status; educational attainment;
household income; and medical, obstetric and supplement
intake (type and duration) history were collected during the
screening visit. Their height, weight, BMI and waist circum-
ference were measured at the booking and OGTT visits. A
random blood sample at booking and fasting and 2 h blood
samples at OGTT using 75 g of anhydrous glucose after an
overnight fast of at least 10 h were taken. As the focus of this
analysis is the diagnosis of GDM, birth outcomes data are not
reported here.
Biochemical analysis
Blood samples were kept in refrigerated containers, centri-
fuged within 30min of collection and stored in −80°C freezers
until analysis, except for glucose which was done immediate-
ly. Plasma glucose was determined by the hexokinase enzy-
matic method using a Synchron CX7 auto-analyser (Beckman
Coulter, Fullerton, CA, USA). Serum B12 and folate were
measured by electro-chemiluminescent immunoassay
(Roche Cobas analyser, Roche Diagnostics, Burgess Hill,
UK). The intra- and inter-assay CVs for B12 and folate were
2.0% and 3.1%; and 3.1% and 3.8%, respectively. Plasma
tHcy was determined by stable isotopic dilution analysis using
a Shimadzu HPLC system with an auto-sampler coupled to
the detection system of an API 6500 QTrap tandem mass
spectrometer (liquid chromatography mass spectrometry
[LCMS]) (Applied Biosystems,Warrington, UK) [28]. A cali-
bration curve and quality control samples (low, medium and
high concentrations within the limits of quantification;
Waters, UK) were set up for each sample batch that was
analysed. Inter- and intra-assay CVs for tHcy were 7.0% and
8.1%. This was comparable to an assay used by a regional
laboratory in Birmingham [29] and below the recommended
CV thresholds [30].
Definitions
Ethnicity was coded using standard definitions. ‘Other’ ethnic
group included North African, Black African, Caribbean,
Asian, South East Asian, Middle Eastern and mixed ethnicity.
GDM diagnoses based on NICE (NICE-GDM; fasting plasma
glucose [FPG] ≥5.6 mmol/l or 2 h post-load plasma glucose
[2 h-PG] ≥7.8 mmol/l) and International Association of
Diabetes and Pregnancy Study Groups (IADPSG) criteria
(IADPSG-GDM; FPG ≥5.1 mmol/l or 2 h-PG ≥8.5 mmol/l)
were recorded [27, 31]. B12 insufficiency was defined using
two different cut-offs: <150 pmol/l and <220 pmol/l. The
former is commonly used to define B12 deficiency in adults
and in pregnancy, while others have suggested the higher cut-
Diabetologia
off in pregnancy, as this was associated with low birthweight
and elevated tHcy and methylmalonic acid (MMA) levels
[32–34]. Folate deficiency was defined as <10 nmol/l and
folate excess as >45 nmol/l [35].
Pre-defined outcomes
Primary
Differences in the risk of GDM in women with and without
early pregnancy B12 insufficiency.
Secondary
1. Associations of B12 and folate with blood glucose level/
GDM risk (B12, folate, FPG and 2h-PG as continuous
variables);
2. Association between tHcy and blood glucose level/GDM
risk;
3. Association between ‘low B12–high folate’ status and
blood glucose level/GDM risk; and
4. Ethnic differences in associations of B12, folate and tHcy
with blood glucose level/GDM risk.
5. We also aimed to assess the role of BMI in these
associations.
Statistical analysis
Sample size calculations There are no published data on the
rate of first trimester B12 insufficiency in GDM women in the
UK. At study design, preliminary results from our group
showed 15% insufficiency (<150 pmol/l) in early pregnancy
and 10–12% prevalence of GDM [27]. To detect a 5% differ-
ence in the prevalence of GDM between normal and B12
insufficiency with 90% power at the 5% significance level,
3822–4322 women were required; we aimed to recruit 4500
women in early pregnancy, allowing for a 10% drop-out rate.
AnalysesWomen’s characteristics were reported using appro-
priate descriptive statistics (mean and SD) or median and IQR
for continuous variables and percentages for categorical vari-
ables. χ2 and t tests were used to assess differences in cate-
gorical and continuous variables, respectively. To define
participants’ socioeconomic status (SES), we considered their
occupation and total household income. For the main outcome
analyses, household income was used as the main measure of
SES, because this is directly associated with higher purchase
and intake of vegetables and fruit which in turn correlate with
higher folate status [36].
RR and 95% CI for GDM in relation to different
micronutrients were estimated using multiple log-binomial
regression models. Multiple linear regression analyses were
used to test the associations of early pregnancy micronutrients
with FPG and 2h-PG at OGTT. The micronutrients were
standardised, by subtracting the mean and dividing by SD,
to aid comparison. To further understand the shapes of the
relationships of FPG and 2h-PG at OGTTwith B12 and folate,
cubic spline regression models were fitted. Ethnic-specific
associations of the micronutrients with glucose levels and
the risk of GDM were tested using similar regression models.
From published studies, while the causal direction is clear
between BMI and glucose, this is not clear between BMI and
B12 and folate. Therefore, to understand this complex inter-
play, two different models were used, a priori, for all the
regression analyses while adjusting for possible confounders.
Model 1 included age, parity, smoking status, ethnicity, fami-
ly history, household income and respective micronutrient
status (B12 for folate, folate for B12, and B12 and folate for
tHcy). Model 2 included model 1 plus BMI. Other possible
confounders such as marital status and gestational weight gain
were not used as they did not contribute to the exploratory
and/or outcome variables. Effects of interaction between B12
and folate on blood glucose level and the risk of GDM were
investigated both as continuous variables and after
categorising them by tertiles. The first tertile of folate and
the third tertile of B12 were used as the reference tertiles.
As the proportion of missing data was low for B12, folate
and tHcy (maximum 2.6%), the main analysis reported
excluded these patients. All analyses were implemented using
R version 4.0.0 [37].
Results
A total of 4746 eligible pregnant women were recruited. Their
mean gestational age was 12.5 ± 1.4 weeks (Fig. 1). Ethnicity
proportions were similar at both the booking and OGTT visits
(Table 1, Fig. 1). B12 insufficiency (42.3%) and folate excess
(36.5%) were common but folate deficiency (1.3%) was rare
in all ethnic groups. BMI was inversely associated with B12
and positively associated with folate and tHcy (electronic
supplementary material [ESM] Table 1). Folic acid and multi-
vitamin supplement usage were associated with higher folate
and B12 levels, respectively, and lower tHcy.While household
income was unrelated to B12 levels, higher income was asso-
ciated with higher folate and lower tHcy levels.
Obesity was the most common reason for selective screen-
ing in white women, and all ethnic minority women were
universally screened as per NICE guidelines (ESM Table 2).
A total of 538 (12.5%) women had NICE-GDM and 633
(14.7%) had IADPSG-GDM. The characteristics of study
participants by GDM status are shown in Table 2 (IADPSG-
GDM). For simplicity, all the NICE-GDM data are presented
in the ESM (ESM Table 3, ESM Fig. 1). Both folic acid and
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multivitamin supplement usage were similar between GDM
and non-GDM groups.
Primary outcome: B12 insufficiency and GDM
Early pregnancy median B12 levels were significantly lower in
women who were later diagnosed to have IADPSG-GDM
(Table 2). B12 insufficiency at <220 pmol/l was associated
with 38.3% higher adjusted RR (aRR) of IADPSG-GDM
(aRR 1.383; 95% CI 1.157, 1.652; p = 0.0004) in model 1
and 20.3% higher in model 2 (aRR 1.203; 95% CI 1.003,
1.443; p = 0.05). The associations with NICE-GDM and with
B12 insufficiency at <150 pmol/l are shown in ESM Table 4.
Secondary outcomes
B12, blood glucose level and GDM The cubic spline graphs
showed that the relationships between B12 and glucose levels
were linear (Fig. 2a,b) and B12 was negatively associated with
FPG, 2h-PG and risk of GDM (Figs 3a,b, 4a). A 1 SD increase
in B12 (116 pmol/l) was associated with a 0.06 mmol/l lower
FPG (95% CI −0.04, −0.08; p < 0.0001), a 0.07 mmol/l lower
2h-PG (95% CI −0.02, −0.12; p = 0.004) and a 14.4% lower
RR of IADPSG-GDM (0.856; 95% CI 0.786, 0.933; p =
0.0004; model 1), after adjusting for key confounders. Effect
sizes halved when adjusted for BMI (model 2; Figs 3a,b, 4a).
Folate, blood glucose level and GDM Folate was positively
associated with blood glucose level, but its associations were
complex. The cubic spline graphs show the different shapes of
these relationships. With FPG, the relationship was U-shaped
(quadratic β: 0.011; p = 0.05) and with 2h-PG it was linear
and significant (Fig. 2c,d). A 1 SD increase in folate
(12.16 nmol/l) was associated with 0.08 mmol/l higher 2 h-
PG (95% CI 0.04, 0.13; p = 0.0005) and 11% higher RR of
IADPSG-GDM (aRR 1.11; 95% CI 1.036, 1.182; p = 0.002)
(model 1; Figs 3c,d, 4b). Similar to B12, its effect size reduced
when adjusted for BMI (model 2; Figs 3c,d, 4b). A sensitivity
analysis, stratified by whether women were taking folate
supplements or not, showed similar results (data not shown).
tHcy, blood glucose level and GDM tHcy was inversely asso-
ciated with blood glucose level and risk of GDM. The associ-
ations strengthened when adjusted for BMI, suggesting that
the tHcy effect on blood glucose level/GDM is independent of
BMI, B12 and folate (ESM Table 5).
Recruited: 4751
Eligible: 4746
White people: 3488 (73.5%)
South Asians: 769 (16.2%)
Others: 489 (10.3%)
GDM status available at OGTT: 4320a
White people: 3188 (73.8%)
South Asians: 697 (16.1%)
Others: 435 (10.1%)
a17 GDM by other means without OGTT
Excluded: 419 (8.8%)
• Miscarried: 118 (terminaon 3)
• Did not aend OGTT: 165
• Declined OGTT: 4
• Not booked: 8
• Unwell during OGTT: 4
• Withdrew consent: 55
• Moved out of area: 56
• Not eligible: 9 (reasons 
unknown: 3; B12 injecons: 2; 
developed other diseases: 4)
Not eligible: 5
• Severe anaemia: 3
• On B12 injecons: 2
Extreme preterm: 
Fig. 1 Study flow diagram
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Low B12–high folate imbalance on blood glucose level and
GDM While no multiplicative interactions were observed
between B12 and folate as continuous variables (interaction
effects on FPG, 2 h-PG, NICE-GDM and IADPSG-GDM
having p values of 0.47, 0.20, 0.83 and 0.49, respectively),
significant interactions were observed when B12 and folate
were categorised as tertiles with RR of NICE-GDM (ESM
Table 6). The opposing associations of B12 and folate with
glucose and GDM result in the highest risk being in women
within the lowest B12 and highest folate tertiles (ESM Fig. 2a–
d). Compared with the ‘B12 tertile3+folate tertile1’ group, the
‘B12 tertile1+folate tertile3’ group had higher levels of FPG
(0.21 mmol/l; p = 0.0001) and 2 h-PG (0.57 mmol/l;
p < 0.0001) and higher aRR of IADPSG-GDM (aRR 1.742;
95% CI 1.226, 2.437; p = 0.003).
Ethnic differences of B12, folate and tHcy in blood glucose
level and GDM risk The B12 associations seemed to be stronger
in South Asians, with a 22% lower RR for IADPSG-GDM in
model 1 (aRR 0.78; 95% CI 0.63, 0.947; p= 0.01) and 14.7% in
model 2 (aRR 0.853; 95% CI 0.689, 1.037; p= 0.12) (Fig. 4a).
The inverse association with FPG was seen in all ethnic groups,
but, for 2h-PG, it was significant only in SouthAsians inmodel 2
(Fig. 3a,b). However, no significant differences were observed
Table 1 Baseline characteristics of the study participants
Maternal characteristic at booking All (N=4746) White people (n=3488) South Asians (n=769) Other (n=489) p value
Age (years) 30.51±5.29 30.1±5.35 31.57±4.72 31.4±5.4 <0.0001
Multiparity (≥2) 919 (19.4) 698 (20.0) 119 (15.5) 102 (20.9) 0.01
Gestational age (weeks) 12.45±1.44 12.39±1.47 12.51±1.39 12.8±1.21 <0.0001
Height (cm) 164.28±6.83 165.32±6.64 160.69±6.24 162.57±6.84 <0.0001
Weight (kg) 83.33±20.49 88.3±19.6 66.44±13.93 74.44±18.04 <0.0001
BMI (kg/m2) 30.8±7.06 32.3±6.92 25.7±4.96 28.1±6.27 <0.0001
Waist circumference (cm)a 98.54±16.41 101.9±15.95 87.73±12.78 91.45±15.16 <0.0001
Biochemical characteristics n=4630 n=3396 n=759 n=475
B12 (pmol/l) 238.2 (183.3–311.2) 230.3 (181.1–298.0) 233.3 (177.9–319.9) 316.5 (237.3–429.3) <0.0001
Folate (nmol/l) 35.9 (24.8–52.2) 33.8 (23.2–51.3) 43.0 (30.4–54.0) 38.3 (27.0–51.6) <0.0001
tHcy (μmol/l)b 11.3 (8.6–14.7) 11.4 (8.7–14.8) 11.1 (8.7–14.7) 10.9 (8.3–13.8) 0.12
B12 insufficiency at <150 pmol/l 490 (10.6) 365 (10.7) 101 (13.3) 23 (4.8) <0.0001
B12 insufficiency at <220 pmol/l 1985 (42.8) 1536 (45.2) 348 (45.8) 98 (20.6) <0.0001
Folate deficiency (<10 nmol/l) 69 (1.5) 61 (1.8) 1 (0.1) 7 (1.5) 0.003
Folate excess (>45 nmol/l) 1640 (35.4) 1139 (33.5) 342 (45.1) 159 (33.5) <0.0001
Using folate supplements 3424 (78.2) 2569 (79.5) 526 (76.0) 329 (72.3) <0.0001
Using multivitamin supplements 2494 (58.1) 1840 (58.2) 425 (62.7) 229 (50.9) <0.0001
Maternal characteristics at OGTT n=4320 n=3396 n=759 n=475
Gestational age (weeks)c 26.79±2.64 26.83±2.63 26.6±2.68 26.76±2.67 0.12
Gestational weight gain (kg)d 5.86±4.75 5.65±4.85 6.59±4.7 6.29±3.85 <0.0001
FPG (mmol/l)e 4.48±0.55 4.49±0.54 4.51±0.56 4.4±0.56 0.002
2h-PG (mmol/l)f 5.88±1.51 5.85±1.47 6.03±1.63 5.8±1.59 0.01
GDM prevalence by NICEg 538 (12.5) 390 (12.2) 95 (13.6) 53 (12.2) 0.59
GDM prevalence by IADPSGg 633 (14.7) 450 (14.1) 127 (18.2) 57 (13.1) 0.01
Data are presented as mean ± SD, median (IQR) or n (%)
‘Other’ ethnic group includes: North African, Black African, Caribbean, Asian, South East Asian, Middle Eastern and mixed ethnicity
p values across all ethnic groups by χ2 test
Variables that have lesser ‘n’ are indicated separately:
a All = 4366, white people = 3213, South Asian = 696, other = 457
bAll = 4612, white people = 3385, South Asian = 753, other = 474
cAll = 4235, white people = 3125, South Asian = 680, other = 430
dAll = 3974, white people = 2953, South Asian = 629, other = 392
eAll = 4303, white people = 3172, South Asian = 696, other = 435
f All = 4275, white people = 3150, South Asian = 692, other = 433
gAll = 4320, white people = 3188, South Asian = 697, other = 435
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between ethnic groups when an interaction function was used
between B12 and ethnicity. The folate association with 2h-PG
seemed to be present in all ethnic groups, but, for the risk of
GDM, it was statistically significant only in white people (Figs
3d, 4b). The tHcy associations with FPG, 2h-PG andGDMwere
present only in white people (data not shown).
Discussion
In this early pregnancy prospective cohort study, we found
that B12 insufficiency and folate excess were common in the
first trimester. B12 levels were lower and folate levels were
higher in women who were subsequently diagnosed to have
GDM, around 27 weeks of gestation. Lower B12 in early preg-
nancy was associated with higher fasting and 2 h glucose
levels as well as a higher RR of GDM. Folate associations
were opposite, and higher folate level was associated with
higher 2h-PG and higher risk of GDM. Approximately half
of the effect sizes were mediated by BMI. These associations
of B12 and folate levels with maternal blood glucose level
were clinically small (between 0.06 and 0.08 mmol/l per
SD) but statistically significant. Although no interactions were
observed for B12 and folate levels (as a continuum) with
glucose and GDM, a combination of low B12 and high folate
tertiles had stronger associations with hyperglycaemia and
Table 2 Characteristics of study participants by IADPSG-GDM
Maternal characteristic All (N=4320) GDM (n=633) Non-GDM (n=3687) p value
Ethnicity
White people 3188 (73.8) 449 (14.1) 2739 (85.9) 0.01
South Asian 697 (16.1) 127 (18.2) 570 (81.8)
Other 435 (10.1) 57 (13.1) 378 (86.9)
Age (years) 30.59±5.23 31.9±5.16 30.36±5.21 <0.0001
Multiparity (≥2) 806 (18.7) 137 (21.6) 669 (18.1) 0.04
Gestational age at booking (weeks) 12.47±1.41 12.36±1.46 12.49±1.4 0.04
Gestational age at OGTT (weeks)a 26.79±2.64 26.07±3.67 26.91±2.4 <0.0001
Height (cm) 164.33±6.85 164.08±6.84 164.37±6.85 0.31
Weight (kg) 83.54±20.46 89.25±20.46 82.56±20.3 <0.0001
BMI (kg/m2) 30.86±7.07 33.05±6.87 30.49±7.03 <0.0001
Waist circumference (cm)b 98.57±16.35 103.98±15.99 97.64±16.23 <0.0001
Gestational weight gain (kg)c 5.86±4.75 5.28±4.45 5.95±4.79 0.001
Using folate supplementsd 3136 (78.5) 482 (81.6) 2654 (78) 0.06
Using multivitamin supplementse 2317 (59.2) 331 (58.3) 1986 (59.4) 0.65
Biochemical characteristics n=4228 n=617 n=3611
B12 (pmol/l) 239.1 (183.76–313.3) 223.7 (179.0–300.3) 242.0 (185.4–315.3) 0.0007
Folate (nmol/l) 36.7 (25.5–52.7) 38.2 (26.9–61.7) 36.2 (25.1–52.1) 0.05
tHcy (μmol/l)f 11.2 (8.6–14.6) 10.9 (8.1–13.9) 11.4 (8.7–14.8) 0.02
B12 insufficiency at <150 pmol/l 436 (10.3) 71 (11.5) 365 (10.1) 0.32
B12 insufficiency at <220 pmol/l 1790 (42.3) 298 (48.3) 1492 (41.3) 0.001
Folate deficiency (<10 nmol/l) 54 (1.3) 9 (1.5) 45 (1.2) 0.81
Folate excess (>45 nmol/l) 1544 (36.5) 240 (38.9) 1304 (36.1) 0.20
Data are presented as mean ± SD, median (IQR) or n (%)
‘Other’ ethnic group includes: North African, Black African, Caribbean, Asian, South East Asian, Middle Eastern and mixed ethnicity
t test was used to compare the continuous variables between GDM and non-GDM. χ2 test was used to compare the categorical variables (ethnicity,
multiparity, B12 insufficiency, folate deficiency and folate excess)
Variables that have lesser ‘n’ are indicated separately:
a All = 4227, GDM = 607, non-GDM = 3620
bAll = 3979, GDM = 583, non-GDM = 3396
cAll = 3968, GDM = 556, non-GDM = 3412
dAll = 3994, GDM = 591, non-GDM = 3403
eAll = 3912, GDM = 568, non-GDM = 3344
f All = 4209, GDM = 613, non-GDM = 3596
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GDM than the individual B12/folate levels. Having a larger
sample size with multiple ethnic groups enabled us to explore
the complex associations of folate with FPG and 2h-PG, and
to clarify previously inconsistent findings with greater
confidence.
Higher FPG and risk of GDM at low B12 levels was present
in all ethnic groups, but the inverse association with 2h-PG
was present mainly in South Asians. Similar inverse relation-
ships at the time of OGTT were observed for B12 with FPG
and insulin resistance in White British women [16], and with
GDM in Indians (living in India and Singapore) [14, 15] and
Italians [25]. In contrast, a recent study showed a direct rela-
tionship between early pregnancy B12 and 1 h and 2 h plasma
glucose levels in a Chinese population. However, this study
did not report its association with FPG or the relationship after
adjusting for BMI or other covariates [21]. In addition, it did
not report the association between B12 and BMI. These factors
may have accounted for the differences, especially due to the
inverse relationship observed between B12 and BMI in our
study. This inverse relationship between B12 and BMI has
been seen in other studies both during [10, 16, 17] and outside
pregnancy [38].
Two recent Mendelian randomisation studies, primarily in
white people, did not demonstrate a causal link between B12
and BMI [39, 40]. FUT2 polymorphisms can influence the
composition of gut microbes [41] which in turn can cause both
obesity and low B12. This was proposed as a potential explana-
tion for the strong observational link but lack of Mendelian
randomisation link between low B12 and high BMI [40]. Our
in vitro studies showed that subcutaneous adipose tissue isolat-
ed at the time of delivery from pregnant women with low B12
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Fig. 2 (a–d) Cubic spline regression analysis of the relationship of early
pregnancy B12 and folate with fasting and 2 h glucose levels at OGTT. (a)
The relationship between B12 and fasting glucose and (b) 2 h glucose and
(c) the relationship between folate and fasting glucose and (d) 2 h glucose
using the cubic spline regression analyses. The regression curve is shown
in bold, and the shaded area represents the 95% confidence band. The
dotted vertical lines represent the reference range for the B12 (150, 220
and 660 pmol/l) and folate levels (10 and 45 nmol/l)
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genes, as well as altered expression of 12 microRNAs
(miRNAs) that regulate the peroxisome proliferator-activated
receptor (PPAR)γ and insulin signalling pathways [38, 42].
These adipose tissue-derived miRNAs were also altered in the
maternal circulation [42], which in turn can affect the beta cell
function and/or hepatic handling of glucose levels [43, 44].
Our study provides clarification for conflicting data that
have been reported recently on maternal folate levels and
GDM risk. Our large sample size enabled us to demonstrate
a U-shaped relationship between folate and FPG levels and
may explain the opposite associations reported in different
populations. High folate levels within the reference range
may be beneficial for FPG but harmful for 2 h-PG, and folate
levels above the reference range appear to be harmful for both.
The relationship of higher folate and higher 2h-PG with GDM
risk is similar to observations reported in Chinese [19–21] and
Indian populations [15] but opposite to that in the American
population [18], which only had estimated folate intake. The
American study was conducted prior to mandatory
folate fortification and hence was unlikely to have had
the high levels of folate observed in our population. It
has been shown that excess folic acid from supplements
results in the presence of unmetabolised folic acid levels
in serum in all age groups [45]. Unmetabolised folic
acid slows the 1-C cycle, reduces the methylation
potential and conversion of methionine, and increases
intracellular accumulation of ATP [46]. This can lead
to reduced insulin-mediated glucose uptake in muscle
cells in vitro and in animal models, resulting in reduced
insulin sensitivity and higher insulin resistance in the
offspring [45, 46]. This may explain the opposite asso-
ciations we observed for folate levels within the refer-
ence range with FPG and 2h-PG levels. In addition, a
‘low B12–high folate’ combination could have compro-
mised the methylation potential further, which is known













































Fig. 3 (a–d) Associations of early
pregnancy B12/folate levels with
fasting and 2 h glucose levels. (a)
The standardised β coefficient of
the associations of early
pregnancy B12 levels (as a
continuum) with fasting glucose
at OGTT and (b) with 2 h glucose
levels. (c) The standardised β
coefficient of the associations of
early pregnancy folate levels (as a
continuum) with fasting glucose
at OGTT and (d) with 2 h glucose
levels. Data are shown with 95%
CI. Two models are shown for
each ethnic group. Circles depict
model 1 and triangles depict
model 2. Model 1 is adjusted for
the following covariates: age,
parity, family history, household
income, smoking and folate.
Model 2 is adjusted for model 1 +
BMI
Diabetologia
tHcy had inverse associations with glucose levels and
adjusting for BMI augmented its effect size on blood glucose
level. Similar inverse associations between tHcy and glucose
levels were also observed recently [15]. We found that higher
BMI is associated with higher tHcy and glucose levels. In
addition, it is known that high tHcy levels can be associated
with low birthweight [49], and 5–7% of offspring of women
with GDM may be small for gestational age [2, 3]. Further
investigations are warranted to understand the complex rela-
tionships among tHcy, glucose levels and birthweight.
Strengths and limitations
The strengths of our study were that it was a large, early
pregnancy, multi-ethnic, prospective cohort in a UK repre-
sentative population, with more than 90% follow-up. We
centrifuged our samples within 30 min, and measured
folate up to 136 nmol/l and tHcy by the LCMS method.
However, our study had the following limitations. First,
we did not have glucose measurements in early pregnancy
or 30 min or 1 h glucose and insulin measurements at
OGTT to further explore the associations of B12/folate
with beta cell function or insulin resistance. Lack of 1 h
glucose levels may have underestimated the IADPSG-
GDM rates. However, we believe this is unlikely to have
influenced our conclusions, as the observed associations
between these B vitamins and glucose levels were contin-
uous. Second, we did not have oxidised folate (or sub-
fractions of folate) measurements. While this is unlikely
to have influenced our results, it may have helped to
explore the relationship between unmetabolised folic acid
and 2 h-PG. Third, the tHcy levels observed seem to be
higher than in other studies. Our first trimester samples
were non-fasted samples. Food is known to increase the
tHcy levels [30]. In addition, our sensitive, LCMS-based
assay could have contributed to these higher levels [50].
Fourth, as our study used NICE selective screening
criteria, two-thirds of white women were screened because
of obesity, and hence our findings may not be applicable
to normal weight white women. Finally, although our
cohort was relatively large, for our ethnic-specific analy-
ses, it was still small, as shown by the wide CIs.
Implications, unanswered questions and future
research
Our study demonstrated that B12 and folate levels may be inde-
pendent, modifiable risk factors for hyperglycaemia in late preg-
nancy. B12 insufficiency is not uncommon in pregnancies across
the world [51]. Our study confirmed this and showed that excess
folate levels are also common, while folate deficiencywas rare in
early pregnancy, highlighting the need to avoid very high folate
levels in early pregnancy. This warrants urgent review of the
dose and duration of folic acid supplements and future research
should focus on: (1) investigating the effect of optimising B12
and folate levels in early pregnancy and before conception on
glucose levels and rate of GDM and/or its complications; (2)
mechanistic studies investigating the effects of food- vs
supplement-derived folate and unmetabolised folic acid levels
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Fig. 4 (a, b) Early pregnancy B12/folate levels and risk of GDM. (a) The
B12 and (b) folate levels in early pregnancy and aRR of IADPSG-GDM.
Data are shown with 95% CI. Two models are shown for each ethnic
group. Circles depict model 1 and triangles depict model 2. Model 1 is
adjusted for the following covariates: age, parity, family history, house-
hold income, smoking and B12. Model 2 is adjusted for model 1 + BMI
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studies designed to explore the complex relationships among
tHcy, BMI, glucose and birthweight.
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but unedited supplementary material available at https://doi.org/10.1007/
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